[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570386":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":38,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Nicola Fusco, MD","Istituto Europeo di Oncologia","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","00390294372079","nicola.fusco@ieo.it",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"francesca lombardi, biologist","00390257489425","francesca.lombardi@ieo.it",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Milan","MI","20141","Italy","IT",{"type":31,"coordinates":32},"Point",[33,34],9.18951,45.46427,{"lat":34,"lon":33},[37],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100570386",false,"NCT06706570","PIK3CA Mutational Status Assessment","PIK3CA Mutational Status Assessment: Towards a \"Tailored\" Diagnostic Approach","Inclusion Criteria:\n\n* Participant has a histologically and\u002For cytologically confirmed diagnosis of ER+ and\u002For PgR+ breast cancer by local laboratory.\n* Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing.\n* Participants should be at advanced or metastatic setting prior to treatment.\n* Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.\n* Patients must be accessible for follow-up.\n\nExclusion Criteria:\n\n• patients already treated with different treatments like chemotherapy, hormone therapy etc","FEMALE","18 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.",[54],"Breast Cancer Metastatic","2026-03-23",{"date":57,"type":58},"2026-03-24","ACTUAL",{"date":60,"type":58},"2024-11-06",{"date":62,"type":50},"2030-12-31",{"name":5,"class":6},1]